Nemolizumab In The Treatment Of Atopic Dermatitis With Moderate To Severe Excoriation
Patent No. EP3749353 (titled "Nemolizumab In The Treatment Of Atopic Dermatitis With Moderate To Severe Excoriation") was filed by Chugai Seiyaku Kabushiki Kaisha on Feb 8, 2019. The application was issued on Jul 30, 2025.
Patent Summary
A pharmaceutical composition for treating atopic dermatitis in subjects with one or more moderate to severe skin excoriations comprises nemolizumab or an equivalent thereof and a pharmaceutically acceptable carrier. An equivalent to nemolizumab is defined as an anti-IL-31RA antibody meeting any of the following criteria: (i) $\ge$55% amino acid sequence identity in heavy chains, (ii) $\ge$55% identity in light chains, (iii) $\ge$55% identity in variable regions, (iv) $\ge$55% identity in complementarity-determining regions (CDRs), (v) binding to the same IL-31RA isoform (optionally the same epitope) as nemolizumab, or (vi) blocking or neutralizing IL-31RA. Nemolizumab is a humanized monoclonal antibody that inhibits interleukin-31 signaling by binding to the IL-31 receptor subunit alpha (IL-31RA).
Patent Family
Patent Oppositions (2)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP3749353
- Application Number
- EP19710488A
- Filing Date
- Feb 8, 2019
- Status
- Granted And Under Opposition
- Jun 27, 2025
- Publication Date
- Jul 30, 2025
- External Links
- Slate, Register , Google Patents